A phase II clinical trial of cixutumumab, a monoclonal antibody to IGF-IR, which showed encouraging therapeutic efficacy for MPM in preclinical study [23], is currently ongoing for the treatment of patients with mesothelioma. The gene discussed is IGF1R; the disease is mesothelioma.